Cupid Ltd. delivered exceptional Q1 FY27 performance with consolidated net profit surging 194% year-on-year to ₹44.15 crore, compared with ₹15.01 crore in Q1 FY26, according to latest market reports. The company's shares surged as much as 2.15% to a fresh high of ₹267.90 on the BSE, hitting a record high after the strong quarterly results. The stock has delivered exceptional returns to investors, with the shares gaining 150.47% so far this year, 212.17% in the last six months, and 683.96% over the past year, according to BSE data. The company has now raised its FY27 guidance, expecting revenue in the range of ₹725-750 crore and net profit of ₹210-225 crore, supported by a strong order book and sustained momentum across its international B2B healthcare and domestic consumer healthcare segments.
Revenue from operations surged 159% YoY to ₹155 crore for Q1 FY27, driven by strong growth in international and domestic healthcare segments. The company's operating income showed equally impressive growth, rising to ₹36.24 crore from ₹5.90 crore in Q1 FY26, representing a 158.04% increase from the year-ago period. Total revenue stood at ₹120.23 crore, up 5.88% quarter-on-quarter and 52.82% year-on-year from ₹93.50 crore in Q4 FY26. The surge in profitability was underpinned by robust demand across its portfolio of male and female condoms, water-based lubricants, and In Vitro Diagnostics (IVD) kits.
Operating performance remained even stronger with EBITDA soaring 265% YoY to ₹60.06 crore from ₹16.47 crore a year ago, with the EBITDA margin expanding to 39% in Q1 FY27 from 28% in the corresponding quarter last year. This margin expansion indicates better operating leverage and an improved product mix. The strong growth in operating income underscores the increasing contribution from core businesses, reinforcing the quality of earnings and sustainability of the growth trajectory. Consolidated net profit stood at ₹44.15 crore, compared to ₹15.01 crore in Q4 FY26, with diluted normalized EPS improving significantly from the previous quarter.
The company reported that FY27 began with strong momentum in international B2B healthcare as well as domestic consumer healthcare and FMCG businesses. According to the company, a strong order book and demand from its international B2B business have provided strong revenue visibility for the coming period. The company also expects to receive large orders from several state governments in India for its IVD kits portfolio, along with significant international opportunities following the receipt of CE certifications. Many of these opportunities are in the final stages of the award process, indicating strong near-term execution potential. The company has also implemented a minimum 10% price increase across its export portfolio, supporting improved realisations and margin expansion, while a favourable USD/INR environment has supported export realisations.
Despite the strong quarterly results, Cupid Limited's shares have demonstrated exceptional long-term performance, with the stock generating multibagger returns for investors. The stock has gained 23% in one month, 96% in three months, 200% in six months, and delivered multibagger returns of 680% over the past year. In the past three years, Cupid stock price has skyrocketed 8,895%, while it has surged by a staggering 10,900% in five years. The company currently has a market capitalisation of more than ₹35,191 crore. The stock was trading at around ₹262.94, close to its 52-week high of ₹267, with capacity expansion, strong order visibility, operating leverage and strategic initiatives expected to strengthen performance during the remaining part of the financial year.
